Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Polasek

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
European Journal of Clinical Pharmacology|August 4, 2009
Assessment of inter-individual variability in predicted phenytoin clearanceThomas M Polasek, Sebastian Polak, Matthew P Doogue, et al.
European Journal of Clinical Pharmacology|July 17, 2014
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactionsBen D Snyder, Andrew Rowland, Thomas M Polasek, et al.
Frontiers in Psychiatry|September 7, 2021
Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health SettingSam Mostafa, Thomas M Polasek, Leslie J Sheffield, et al.
Clinical Pharmacology and Therapeutics|May 7, 2026
A Review of Virtual Twins in Physiologically-Based Pharmacokinetic Modeling and SimulationEmily Mannix, Sam Mostafa, Amin Rostami-Hodjegan, et al.
Clinical Pharmacology in Drug Development|December 1, 2018
Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug DevelopmentThomas M Polasek, Craig R Rayner, Richard W Peck, et al.
Clinical Pharmacokinetics|December 10, 2024
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps BackwardsIvan Tiryannik, Aki T Heikkinen, Iain Gardner, et al.
European Journal of Clinical Pharmacology|February 10, 2011
In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearanceNitsupa Wattanachai, Thomas M Polasek, Tahlia M Heath, et al.
British Journal of Clinical Pharmacology|August 29, 2012
Predicted metabolic drug clearance with increasing adult ageThomas M Polasek, Farhaan Patel, Berit P Jensen, et al.
Clinical Pharmacology in Drug Development|March 20, 2023
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 StudyThomas M Polasek, Indika Leelasena, Irina Betscheider, et al.
Clinical Pharmacology in Drug Development|January 16, 2026
Effects of Gastric Acid Suppression, Cytochrome P4503A Inhibition and Induction, and Food on the Pharmacokinetics of Tinlarebant in Healthy AdultsThomas M Polasek, Kushal J Paneliya, Tom Lin, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
European Journal of Clinical Pharmacology|August 4, 2009
Assessment of inter-individual variability in predicted phenytoin clearanceThomas M Polasek, Sebastian Polak, Matthew P Doogue, et al.
European Journal of Clinical Pharmacology|July 17, 2014
Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactionsBen D Snyder, Andrew Rowland, Thomas M Polasek, et al.
Frontiers in Psychiatry|September 7, 2021
Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health SettingSam Mostafa, Thomas M Polasek, Leslie J Sheffield, et al.
Clinical Pharmacology and Therapeutics|May 7, 2026
A Review of Virtual Twins in Physiologically-Based Pharmacokinetic Modeling and SimulationEmily Mannix, Sam Mostafa, Amin Rostami-Hodjegan, et al.
Clinical Pharmacology in Drug Development|December 1, 2018
Toward Dynamic Prescribing Information: Codevelopment of Companion Model-Informed Precision Dosing Tools in Drug DevelopmentThomas M Polasek, Craig R Rayner, Richard W Peck, et al.
Clinical Pharmacokinetics|December 10, 2024
Static Versus Dynamic Model Predictions of Competitive Inhibitory Metabolic Drug-Drug Interactions via Cytochromes P450: One Step Forward and Two Steps BackwardsIvan Tiryannik, Aki T Heikkinen, Iain Gardner, et al.
European Journal of Clinical Pharmacology|February 10, 2011
In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearanceNitsupa Wattanachai, Thomas M Polasek, Tahlia M Heath, et al.
British Journal of Clinical Pharmacology|August 29, 2012
Predicted metabolic drug clearance with increasing adult ageThomas M Polasek, Farhaan Patel, Berit P Jensen, et al.
Clinical Pharmacology in Drug Development|March 20, 2023
Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 StudyThomas M Polasek, Indika Leelasena, Irina Betscheider, et al.
Clinical Pharmacology in Drug Development|January 16, 2026
Effects of Gastric Acid Suppression, Cytochrome P4503A Inhibition and Induction, and Food on the Pharmacokinetics of Tinlarebant in Healthy AdultsThomas M Polasek, Kushal J Paneliya, Tom Lin, et al.
Pageof 8